Narrative review explores engineered exosomes for bone disorders, notes translational challenges

This publication is a narrative review exploring the potential of engineered exosomes as therapeutic agents for various bone-related disorders, including osteoarthritis, osteoporosis, fracture healing, bone malignancies, nonunion bone defects, and bone tumors. The review synthesizes preclinical and theoretical evidence rather than reporting on specific clinical trials or patient populations.

The authors discuss several proposed mechanisms through which engineered exosomes might exert therapeutic effects in bone disorders. These include promotion of osteogenesis (bone formation), angiogenesis (blood vessel formation), immunomodulation, anti-inflammatory effects, regulation of autophagy, and regulation of apoptosis. The review presents these as potential pathways based on existing preclinical research rather than as established clinical outcomes.

Significant limitations and translational challenges are acknowledged throughout the review. The authors note several barriers to clinical application including product heterogeneity, challenges in scalable manufacturing, cargo stability issues, difficulties controlling release kinetics, and concerns about long-term safety. These limitations highlight the gap between preclinical promise and clinical reality for engineered exosome therapies.

The review serves as a conceptual overview of a developing field rather than providing evidence-based clinical guidance. Without clinical trial data, safety information, or specific therapeutic protocols, the practice relevance remains speculative. Clinicians should interpret these findings as describing early-stage research directions rather than established treatment approaches for bone disorders.